Duhao Net

Duhao Net helps individual entrepreneurs and enterprises find high-quality suppliers, reduce procurement costs, and make transactions easier.

Fujian Genohope Biotech Ltd.: China HP API Manufacturer and Semaglutide & Tirzepatide factory

Release time：2024-09-23 17:37:31 Source：DuHao

Contact Us Today

Tel : +86-0594-5880288-3416

Email: net.fei@163.com

Address: NO.288,Renyang, Binglun Village, Hushi Town, Xiuyu DistrictPutian City, Fujian Province 351146, China (CHN)

Factory Highlights:

Fujian Genohope Biotech Ltd., established on January 14, 2019, represents a pioneering high-tech biopharmaceutical initiative in Taiwan, strategically located in Putian City, Fujian Province. A joint venture between Taiwan’s Lin Yang Biotech Pharmaceutical Co., Ltd. and New Hope Medical Fund, the company specializes in the production of peptide and protein APIs, with a focus on semaglutide—a leading GLP-1 medication for managing type 2 diabetes and weight loss. Equipped with cutting-edge facilities that meet US GMP standards, Genohope is the world’s first manufacturer to register both recombinant and fully synthetic processes for semaglutide. With an annual production capacity projected to reach 3 tons, the company is positioned to meet the growing global demand for innovative biopharmaceutical solutions, underpinned by a commitment to quality and advanced research and development capabilities.

Factory Highlights:

Location: Putian City, Fujian Province, China.

Standards: The facility adheres to US GMP (Good Manufacturing Practice) and has successfully passed inspections by the US FDA, making it the first sterile injection pharmaceutical company in Fujian Province to achieve this certification.

Production Capacity: The current production line can yield approximately 800 kilograms of semaglutide per year, with plans to expand capacity significantly. The first phase of the Jinuohoupu Peptide Park includes 12 production lines with an annual output nearing 1 ton of peptide APIs, generating an estimated output value of 1 billion yuan.

Products:

Semaglutide

Type: Fully synthetic and semi-fermented semi-synthetic peptide drug.

Indications: Primarily used for treating adult type 2 diabetes, facilitating weight loss, and supporting cardiovascular health.

Market Presence: Approved for marketing in over 50 countries, including the US, Europe, Canada, and Japan. In 2023, global sales of semaglutide reached approximately USD 21.2 billion.

Other Peptide APIs

Tirzepatide: Recently entering scale-up production, this dual-target drug is designed for glucose lowering and weight management, similar to semaglutide, with an expected annual output of 240 kilograms.

Future Developments: Fujian Genohope Biotech Ltd. has a robust pipeline with 51 drugs and APIs currently under development, including collaborations with major Taiwanese biotechnology talents and medical institutions.

DuHao Net